Paying users zone. Data is covered by .

  • Get to Allergan PLC for $13.99, or

  • get to whole website for at least 3 months from $49.99.

 

$13.99

Common-Size Income Statement

Difficulty: Beginner

Allergan PLC, Common-Size Consolidated Income Statement

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net revenues                    
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights                    
Gross profit % % % % %
Research and development                    
Selling and marketing                    
General and administrative                    
Amortization                    
Goodwill impairments                    
In-process research and development impairments                    
Loss on assets held for sale                    
Asset sales and impairments, net                    
Operating loss % % % % %
Interest income                    
Interest expense                    
Teva Share Activity                    
Debt extinguishment costs as part of the debt tender offer                    
Debt extinguishment other                    
Other-than-temporary impairments                    
Dividend income                    
Naurex recovery                    
Forward sale of Teva shares                    
Pfizer termination fee, Allergan plc only                    
Bridge loan commitment fee                    
Interest rate lock                    
Gain (loss) on sale of assets                    
Other                    
Other income (expense), net % % % % %
Loss before income taxes and noncontrolling interest % % % % %
Provision (benefit) for income taxes                    
Net loss from continuing operations, net of tax % % % % %
Income (loss) from discontinued operations, net of tax                    
Net income (loss) % % % % %
(Income) loss attributable to noncontrolling interest                    
Net income (loss) attributable to shareholders % % % % %
Dividends on preferred shares                    
Net income (loss) attributable to ordinary shareholders % % % % %

Top